News >

Baz Highlights Emerging Regimens in Relapsed/Refractory Myeloma

Caroline Seymour
Published: Friday, Sep 07, 2018

Rachid Baz, MD

Rachid Baz, MD
Patients with relapsed/refractory multiple myeloma have a plethora of options based on positive findings from the ARROW, ELOQUENT-3, and OPTIMISMM trials, calling attention to the importance of dosing, scheduling, and choice of regimen, explained Rachid Baz, MD.

“There is no real algorithm on how to manage relapsed/refractory multiple myeloma,” said Baz. “However, those studies add to the therapeutic armamentarium that we have and to the options that patients have when they face their disease.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication